GSK commences phase III study of mepolizumab in severe HES patients
The trial will feature 80-120 patients having the severe form of the disease who will be randomized to receive treatment with either mepolizumab or placebo when added to the
GSK has entered an exclusive strategic partnership with SBP Group, via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ), to expedite the launch of bepirovirsen for chronic hepatitis B (CHB) patients in mainland China.